Synthetic biology opens entirely new possibilities in this context. It enables the design of biological systems either through genetic modification of existing cells (“top-down”) or through the construction of novel systems from minimal molecular components (“bottom-up”). The latter approach—bottom-up synthetic immunology—is emerging as a promising field that applies nanotechnology tools to engineer immune functions from scratch, with high precision and control.

While top-down strategies, such as CAR T cell therapies, have already achieved clinical success, they are often limited to ex vivo applications and are subject to the immune system’s complex self-regulatory networks. Bottom-up approaches, on the other hand, offer the potential for greater specificity and flexibility—for example, through the use of mRNA and lipid nanoparticles as seen in modern vaccines. Future systems could include intelligent modules capable of sensing, computing, and actuating responses in real time, with capabilities like targeted delivery, controlled release, and autonomous function.

Pursuing this vision, overarching goal of the cluster of excellence SynthImmune is to apply synthetic biology comprehensively to immunology in order to develop and validate a new class of synthetic therapeutics. These therapies will be designed to improve the prevention and treatment of AIDS, malaria, brain cancer and pancreatic cancer. By defining the fundamental principles of immune control and creating engineered immune systems with tailored functions, bottom-up synthetic immunology holds the promise to revolutionize how we understand and treat some of the world’s most pressing diseases.

To this end SynthImmune will establish and advance this emerging field by combining expertise in synthetic biology, immunology, and nanotechnology. Bringing together leading institutions in Heidelberg and Mannheim — including Heidelberg University, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Heidelberg Institute for Theoretical Studies (H-IST), European Molecular Biology Laboratory (EMBL) and Max-Planck Institute for Medical Research (MPImF) — SynthImmune establishes a network for cutting-edge research, interdisciplinary training, and clinical translation.

Involved Institutions:

• European Molecular Biology Laboratory (EMBL)
• German Cancer Research Center (DKFZ)
• Heidelberg Institute for Theoretical Studies (HITS)
• Max Planck Institute for Medical Research